Cypherpunk Technologies Earnings Call Transcripts
Fiscal Year 2025
-
A virtual special meeting addressed proposals to increase authorized shares, conduct a reverse split, adopt a new equity plan, and approve a private placement. All proposals were voted on with a quorum present, and preliminary results were announced.
-
Sirexatamab shows promising efficacy and tolerability in metastatic colorectal cancer, especially in patients with high plasma DKK1 or who are VEGF-naive, with improved response rates and progression-free survival over standard care. Ongoing data suggest durable benefit and support further phase 3 evaluation.
-
Sirexatamab plus standard therapy showed a significant ORR improvement in second-line colorectal cancer, especially in DKK1-high, VEGF-naive, and EGFR-experienced subgroups. DKK1 levels strongly correlated with response, supporting phase III planning in CRC, while gastric cancer development will not proceed to phase III.
-
Leap’s lead antibody, now named sirexatamab, is advancing in two pivotal trials for gastric and colorectal cancer, with promising early results, especially in bevacizumab-naive and left-sided colorectal cancer patients. The FL-501 program for cancer cachexia is also progressing, with preclinical data expected soon.
Fiscal Year 2024
-
Lead asset DKN-01 is advancing in phase 2 trials for gastric and colorectal cancers, with key data readouts expected late 2024 to mid-2025. Subgroup analyses and strategic partnerships are central to future phase 3 plans, while pipeline expansion includes a novel GDF15 antibody.